![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZDHHC15 |
Gene summary for ZDHHC15 |
![]() |
Gene information | Species | Human | Gene symbol | ZDHHC15 | Gene ID | 158866 |
Gene name | zinc finger DHHC-type palmitoyltransferase 15 | |
Gene Alias | DHHC15 | |
Cytomap | Xq13.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | B3KY34 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
158866 | ZDHHC15 | HCC1 | Human | Liver | HCC | 3.73e-11 | 1.05e+00 | 0.5336 |
158866 | ZDHHC15 | HCC2 | Human | Liver | HCC | 1.66e-15 | 1.03e+00 | 0.5341 |
158866 | ZDHHC15 | HCC5 | Human | Liver | HCC | 4.16e-25 | 1.58e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
GO:00421571 | Liver | HCC | lipoprotein metabolic process | 86/7958 | 135/18723 | 5.21e-07 | 8.38e-06 | 86 |
GO:003134611 | Liver | HCC | positive regulation of cell projection organization | 193/7958 | 353/18723 | 2.28e-06 | 3.08e-05 | 193 |
GO:003406721 | Liver | HCC | protein localization to Golgi apparatus | 23/7958 | 29/18723 | 5.86e-05 | 5.38e-04 | 23 |
GO:00421581 | Liver | HCC | lipoprotein biosynthetic process | 58/7958 | 96/18723 | 2.99e-04 | 2.13e-03 | 58 |
GO:00066121 | Liver | HCC | protein targeting to membrane | 75/7958 | 131/18723 | 4.58e-04 | 3.04e-03 | 75 |
GO:00064971 | Liver | HCC | protein lipidation | 55/7958 | 92/18723 | 6.12e-04 | 3.82e-03 | 55 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:0010976 | Liver | HCC | positive regulation of neuron projection development | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
GO:006099611 | Liver | HCC | dendritic spine development | 54/7958 | 99/18723 | 1.03e-02 | 3.86e-02 | 54 |
GO:001635811 | Liver | HCC | dendrite development | 121/7958 | 243/18723 | 1.26e-02 | 4.56e-02 | 121 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZDHHC15 | SNV | Missense_Mutation | c.62N>A | p.Ser21Tyr | p.S21Y | Q96MV8 | protein_coding | tolerated(0.37) | benign(0.01) | TCGA-22-4601-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ZDHHC15 | SNV | Missense_Mutation | novel | c.634N>A | p.His212Asn | p.H212N | Q96MV8 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-33-AAS8-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZDHHC15 | SNV | Missense_Mutation | c.655N>T | p.Val219Leu | p.V219L | Q96MV8 | protein_coding | deleterious(0.05) | benign(0.097) | TCGA-56-6545-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZDHHC15 | SNV | Missense_Mutation | novel | c.470A>T | p.His157Leu | p.H157L | Q96MV8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-98-8021-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZDHHC15 | SNV | Missense_Mutation | novel | c.682N>T | p.Val228Leu | p.V228L | Q96MV8 | protein_coding | tolerated(1) | benign(0.003) | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ZDHHC15 | SNV | Missense_Mutation | c.488N>G | p.Asn163Ser | p.N163S | Q96MV8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B7-5816-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZDHHC15 | SNV | Missense_Mutation | c.421N>T | p.Arg141Cys | p.R141C | Q96MV8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BR-4256-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZDHHC15 | SNV | Missense_Mutation | c.860N>A | p.Ser287Tyr | p.S287Y | Q96MV8 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-BR-6852-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZDHHC15 | SNV | Missense_Mutation | c.202N>G | p.Phe68Val | p.F68V | Q96MV8 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-D7-6822-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZDHHC15 | SNV | Missense_Mutation | c.619N>A | p.Val207Ile | p.V207I | Q96MV8 | protein_coding | tolerated(0.14) | benign(0.158) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |